The primary responsibility of the ECOG-ACRIN Cancer Research Group’s seven-member Nominating Committee is to prepare the Principal Investigator (PI) Committee for the election of new Group Co-Chairs, as needed. In the unlikely event that the need arises for a Group Co-Chair to be recalled, the Nominating Committee also oversees this process.
All seven members of the Nominating Committee are elected (there are no Group Co-Chair appointments). The PI Committee elects a Nominating Committee every two years from a slate of candidates proposed by the Executive Committee. This interaction between the two governance committees provides the Group with checks and balances within the election process. While the Executive and PI Committee both function under the chairmanship of the Group Co-Chairs, the Nominating Committee is entirely independent in its role to nominate and elect new leaders.
The table below lists the current members of the Nominating Committee and the constituency they represent. This committee began its two-year term on October 26, 2017. It is currently in the process of selecting its own chair, and we will update the table soon with leadership information.
Thomas M. Habermann, MD
Mayo Clinic Cancer Center
|Gary I. Cohen, MD|
Greater Baltimore Medical Center, an affiliate of The Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University
|Paul B. Gilman, MD|
Main Line Health NCORP*
|Stanley R. Hamilton, MD|
The University of Texas and the MD Anderson Cancer Center
|Kurt R. Oettel, MD|
Gundersen Lutheran Health System
|Anthony F. Shields, MD, PhD|
Wayne State University and the Barbara Ann Karmanos Cancer Institute
|Heather A. Wakelee, MD|
Stanford University and the Stanford Cancer Institute
|Scientific Planning and Review|
|Biostatistics and Data Management|
|Active Clinical Trials|